

## Cost-effectiveness of screening with transcriptional signatures for incipient TB among U.S. migrants

Yuli Lily Hsieh MPH,<sup>1,2</sup> C Robert Horsburgh Jr MD,<sup>3</sup> Ted Cohen DPH,<sup>4</sup> Jeffrey W Miller PhD,<sup>5</sup> Joshua A Salomon PhD,<sup>6</sup> Nicolas A Menzies PhD<sup>2,7</sup>

1. Interfaculty Initiatives in Health Policy, Harvard University, Cambridge, USA.
2. Harvard Center for Health Decision Science, Boston, USA
3. Departments of Global Health, Epidemiology, Biostatistics, and Medicine, Boston University, Boston, USA
4. Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, USA
5. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA
6. Department of Health Policy, Stanford University School of Medicine, Stanford, USA
7. Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, USA

**Corresponding author:** Yuli Lily Hsieh

Address: 718 Huntington Avenue, Boston, MA USA

Email: [yuli.lily.hsieh@gmail.com](mailto:yuli.lily.hsieh@gmail.com)

Tel: +1 203 285 9951

**Author contributions:** YLH, NAM, CRH, TC, and JAS conceived the study. YLH developed the study approach. NAM, CRH, TC, and JAS helped refine the study objectives and study approach. NAM helped gain access to the TB risk model data. YLH and NAM had access to all the data in the study. YLH performed the statistical and modelling analyses. All authors contributed to the interpretation and presentation of study results. YLH wrote the first draft of the manuscript and all authors reviewed, edited, and approved the final version of the manuscript. All authors had final responsibility for the decision to submit for publication.

**Funding:** This work was supported through grants provided by the US National Institutes of Health/ National Institute of Allergy and Infectious Diseases to NAM (R01AI146555) and the Social Sciences and Humanities Research Council of Canada Doctoral Fellowship to YLH (752-2022-0285). We declare no competing interests.

**Running title:** CEA of screening with HrTS among U.S. migrants

1 **ABSTRACT**

2 **Introduction:** Host-response-based transcriptional signatures (HrTS) have been developed to  
3 identify “incipient tuberculosis (TB)”. No study has reported the cost-effectiveness of HrTS for  
4 post-arrival migrant screening programs in low-incidence countries.

5 **Objectives:** To assess the potential health impact and cost-effectiveness of HrTS for post-  
6 arrival TB infection screening among new migrants in the United States.

7 **Methods:** We used a discrete-event simulation model to compare four strategies: (1) no  
8 screening for TB infection or incipient TB; (2) ‘IGRA-only’, screen all with interferon gamma  
9 release assay (IGRA), provide TB preventive treatment for IGRA-positives; (3) ‘IGRA-HrTS’,  
10 screen all with IGRA followed by HrTS for IGRA-positives, provide incipient TB treatment for  
11 individuals testing positive with both tests; and (4) ‘HrTS-only’, screen all with HrTS, provide  
12 incipient TB treatment for HrTS-positives. We assessed outcomes over the lifetime of migrants  
13 entering the U.S. in 2019, assuming HrTS met the WHO Target Product Profile (TPP) optimal  
14 criteria. We conducted sensitivity analyses to evaluate the robustness of results.

15 **Results:** The IGRA-only strategy dominated the HrTS-based strategies under both healthcare  
16 sector and societal perspectives, with an incremental cost-effectiveness ratio of \$78,943 and  
17 \$89,431 per quality-adjusted life-years (QALY) gained, respectively. This conclusion was robust  
18 to varying costs (\$15–300) and characteristics of HrTS, and the willingness-to-pay threshold  
19 (\$30,000–150,000/ QALY gained), but sensitive to the rate of decline in TB progression risk  
20 after U.S. entry.

21 **Conclusions:** Our findings suggest that HrTS meeting the WHO TPP is unlikely to be a cost-  
22 effective component of post-arrival screening for migrants entering the U.S.

## 23 Introduction

24 Without preventive treatment, approximately 5-10% of healthy individuals infected with  
25 *Mycobacterium tuberculosis* (*Mtb*) will progress to tuberculosis (TB) disease during their  
26 lifetime.<sup>1,2</sup> Current WHO guidelines recommend targeting TB preventive treatment to infected  
27 persons at highest risk of disease progression. However, current tests for *Mtb* infection,  
28 including the interferon gamma release assay (IGRA) and tuberculin skin test (TST), have low  
29 positive predictive values for the proximal onset of TB disease, with only 1-6% of individuals  
30 identified with these tests developing TB within two years.<sup>3-6</sup> The lack of tools for predicting TB  
31 disease limits the ability of TB programs to target preventive treatment to those at highest risk.  
32  
33 In recent years, host-response-based transcriptional signatures (henceforth, HrTS) have been  
34 investigated for their potential to identify “incipient TB” based on the association between  
35 changes in host transcriptome and risk of disease progression.<sup>7,8</sup> Incipient TB has been defined  
36 as “*Mtb* infection that is likely to progress to TB disease in the absence of further intervention  
37 but has not yet induced clinical symptoms, radiographic abnormalities, or microbiologic  
38 evidence consistent with TB disease”.<sup>9</sup> If HrTS can distinguish incipient TB from non-  
39 progressing *Mtb* infection, these tests could facilitate more targeted delivery of interventions to  
40 prevent disease progression. WHO has established a Target Product Profile (TPP) for this class  
41 of tests, recommending sensitivity and specificity of at least 75% (minimum criteria), and ideally  
42 90% (optimal criteria), for distinguishing individuals who would progress to TB disease within  
43 two years.<sup>7</sup>

44  
45 One potential use case of HrTS is for targeting TB preventive treatment among migrants from  
46 countries with high TB incidence moving to lower TB incidence settings. In many low-incidence  
47 countries, migrants have elevated TB incidence rates as a result of infection acquired before or  
48 during migration.<sup>10</sup> For example, in the United States, 71% of reported TB cases between 2017

49 and 2021 occurred in non-US-born persons,<sup>11</sup> and most were attributable to infection acquired  
50 before entry.<sup>12</sup> Screening and treatment of *Mtb* infection in high-risk migrant populations has  
51 been identified as a key component in global tuberculosis control effort.<sup>13</sup> In this setting, HrTS  
52 may be useful as a rule-out test to reduce the need to treat all individuals with a positive IGRA  
53 result, the majority of whom are at very low risk of proximal progression. It could also be used  
54 as a stand-alone rule-in test for incipient TB. To the best of our knowledge, no study has  
55 evaluated the cost-effectiveness of such a test as a post-arrival screening tool for *Mtb* infection  
56 among migrants to low-TB burden countries.

57  
58 In this study, we assessed the potential health impact and cost-effectiveness of four post-arrival  
59 screening strategies for *Mtb* infection among new U.S. migrants, using a potential HrTS that  
60 meets the WHO TPP optimal criteria. To compare these strategies, we used a decision analytic  
61 framework with a discrete-event simulation (DES) model. We parameterized this model with  
62 data for the 2019 immigrant cohort to estimate lifetime TB-related health outcomes and health  
63 service utilization under each screening scenario.

64

## 65 **Methods**

66 **Study Population.** Our simulated study cohort (n = 2,042,225) included migrants whose annual  
67 TB risk could be estimated from a published TB risk model as a function of migrants' country-of-  
68 origin, entry year, age at entry, and number of years since entry to the U.S.<sup>14</sup> Our study cohort  
69 represented 97 countries-of-origin, accounting for 70.6% of the 2019 entry cohort and the  
70 majority of TB cases among this population. The population sizes by age and country-of-origin  
71 were estimated from 2019 American Community Survey data. We divided the study population  
72 into four risk categories based on WHO-estimated country-of-origin TB incidence rates in 2019  
73 (I, 0-9.9; II, 10-99.9; III, 100-299.9; and IV,  $\geq 300$  per 100,000). We conducted our analyses for

74 the entire study cohort and by risk category (Table 1). Further details are given in Appendix 1 in  
75 the online supplement.

76

77 **Intervention Strategies.** We compared four post-arrival screening strategies: (I) no screening  
78 for TB infection or incipient TB ('no screening'); (II) screen all with IGRA, provide TB preventive  
79 treatment for individuals testing positive ('IGRA-only'); (III) screen all with IGRA followed by  
80 HrTS for IGRA-positive persons, provide incipient TB treatment for individuals testing positive  
81 with both tests ('IGRA-HrTS'); and (IV) screen all with HrTS, provide incipient TB treatment for  
82 individuals testing positive ('HrTS-only'). Screening was assumed to occur one month after U.S.  
83 arrival. Strategies II - IV also assumed screening and treatment for TB disease prior to provision  
84 of TB preventive treatment or incipient TB treatment. We assumed that, if diagnosed, TB  
85 disease would be treated with a standard first line treatment, *Mtb* infection would be treated with  
86 once-weekly isoniazid-rifapentine for 12 weeks, and incipient TB would be treated with one  
87 month of daily isoniazid-rifampicin followed by three months of isoniazid-rifampicin thrice  
88 weekly.<sup>15</sup> Table 2 summarizes clinical decision rules, and Appendix 2 in the online supplement  
89 provides a flowchart for each strategy.

90

91 For IGRA, we defined sensitivity and specificity with respect to the *Mtb* infection status at the  
92 time of testing. We assumed IGRA would be positive in 98.5% of individuals with *Mtb* infection  
93 and negative in 78.9% of individuals without *Mtb* infection.<sup>16</sup> For HrTS, we defined sensitivity  
94 and specificity of HrTS with respect to prevalent and future TB disease. For specificity, we  
95 assumed that HrTS would be negative in 90% of individuals without infection or with infection  
96 that would not lead to disease before death. We assumed HrTS would have a sensitivity of 90%  
97 for prevalent TB as well as TB cases occurring within two years of testing, and a sensitivity of  
98 10% for cases occurring subsequently. This assumption implies the test cannot distinguish  
99 individuals who will from those who will not develop TB disease beyond the two-year predictive

100 period, consistent with the reported performance of current signatures.<sup>17</sup> Further, we assumed  
101 independence in IGRA and HrTS test results, conditional on an individual's TB-related health  
102 status at the time of testing ((1) no *Mtb* infection, (2) *Mtb* infection that will not progress to TB  
103 disease during lifetime, (3) *Mtb* infection that will progress within two years (incipient TB), (4)  
104 *Mtb* infection that will progress after two years, (5) prevalent TB disease).

105

106 **Discrete Event Simulation (DES) Model.** Each migrant in the study population was  
107 represented as an individual in the DES model, characterized by country-of-origin, entry age,  
108 and initial health state upon U.S. arrival. The three possible initial health states were: (1) no *Mtb*  
109 infection, (2) *Mtb* infection without TB disease, (3) TB disease. Initial health states were  
110 assigned based on estimated prevalence of *Mtb* infection and estimated incidence of TB  
111 disease, by age and country-of-origin. To parameterize progression from *Mtb* infection to TB  
112 disease, we estimated individual TB risk over time by applying the demographic data of the  
113 2019 entry cohort to the fitted TB risk model reported in Hill *et al.*<sup>14</sup> This empirical study  
114 estimated TB incidence rates among U.S. migrants after entry to the country, as a function of  
115 entry year, entry age, country-of-origin, and time since entry (Appendix 1 in the online  
116 supplement).

117

118 To estimate *Mtb* infection prevalence of by country-of-origin and age group, we fit a functional  
119 relationship between *Mtb* infection prevalence and TB incidence rate using data reported by the  
120 U.S. TB Epidemiological Studies Consortium,<sup>18</sup> and calibrated this to match the overall  
121 prevalence of *Mtb* infection in the non-US-born population.<sup>19</sup> See Appendix 3 in the online  
122 supplement for details. The fraction of migrants entering the US with TB disease was based on  
123 the number of TB cases diagnosed in the 6 months following U.S. entry, estimated using the  
124 published TB risk model.<sup>14</sup>

125

126 At the beginning of the simulation, each individual was assigned a time-to-TB value, drawn  
127 randomly from empirical survival functions of TB incidence, described in Appendix 4 in the  
128 online supplement. Each individual was also assigned a time-to-death value, drawn from  
129 survival functions derived from the 2017 U.S. Life Tables for non-US-born individuals.<sup>20</sup> Whether  
130 a simulated individual would develop TB disease in their lifetime was determined by the  
131 Gillespie algorithm:<sup>21</sup> in the absence of intervention, those with a time-to-TB shorter than the  
132 time-to-death were expected to develop TB during their lifetime. Event data from U.S. entry to  
133 death were simulated and recorded for all modelled individuals. The model was developed in  
134 R.<sup>22</sup> Appendix 5 in the online supplement reports parameter values.

135  
136 **Positive predictive value and negative predictive value.** For each screening strategy, we  
137 calculated the positive predictive value (PPV) and negative predictive value (NPV) of ever  
138 having TB in their lifetime, including prevalent TB disease at the time of testing. Additionally, we  
139 estimated the PPV and NPV of having TB disease within two years of testing, including  
140 prevalent TB disease.

141  
142 **Health outcomes and economic evaluation.** We estimated the number of TB cases averted,  
143 quality adjusted life years (QALYs) gained, number of each test administered, and number of  
144 each treatment prescribed under each strategy. In the base case scenario, IGRA and HrTS  
145 were \$62 and \$30 in 2021 U.S. dollars, respectively. Other healthcare related and non-  
146 healthcare related costs are in Appendix 5 in the online supplement. We conducted a cost-  
147 effectiveness analysis from both societal and healthcare sector perspectives, with costs and  
148 QALYs discounted at 3% annually.<sup>23</sup> We also calculated the net monetary benefit (total  
149 monetized health benefits minus total societal costs) for each strategy with health gains valued  
150 at US\$150,000 per QALY,<sup>24</sup> and other values considered in sensitivity analyses. Appendix 7 in  
151 the online supplement provides an impact inventory and additional costing methods.

152

153 **Sensitivity Analysis.** We conducted probabilistic sensitivity analysis (PSA) to determine the  
154 robustness of our results to collective uncertainty in all parameter inputs, generating 1000  
155 simulated values for all cohort outcomes.<sup>25</sup> The distributions of parameters included in the PSA  
156 are in Table E3 in the online supplement. We conducted an additional two-way sensitivity  
157 analysis over the cost of HrTS (US\$15 – \$300) and willingness-to-pay threshold (\$30,000 –  
158 \$150,000 per QALY gained). We also performed a multi-way sensitivity analysis across  
159 plausible ranges of sensitivity (75 – 100%), specificity (75 – 100%), and cost of HrTS (\$15 –  
160 \$300), along with the timeframe over which the sensitivity value holds (2 – 10 years) and the  
161 willingness-to-pay threshold. The multi-way sensitivity analysis helps inform whether and under  
162 what circumstances the HrTS strategies would be cost-effective. Finally, we estimated results  
163 for an alternative scenario that assumed a more rapid decline in the rate of progression to TB  
164 disease with increasing years since U.S. entry. In this scenario, the annual number of TB cases  
165 remained the same as in the main analysis, but the proportion of cases attributable to a pre-  
166 existing infection was assumed to decline by 3.4% with each additional year since entry. The  
167 remainder were assumed to result from TB (re)infection after U.S. entry, and could not be  
168 averted by the modelled interventions. See Appendix 10 for details.

169

170 Point estimates for all reported outcomes were calculated as the mean of the 1000 values  
171 generated by the PSA, with uncertainties expressed in 95% credible intervals, unless otherwise  
172 specified. The incremental cost-effectiveness ratio (ICER) was calculated as the ratio of the  
173 mean of incremental cost to the mean of the incremental QALY gained.

174

## 175 **Results**

176 **Expected number of TB cases identified by years since entry.** The median age at entry of  
177 the study cohort was 29 years old, and the estimated LTBI prevalence was 12.4% (95% credible



178 interval (CI), 8.5 to 43.5). Under the no-screening strategy, we projected 5601 (3667 to 8177)  
179 members of the study cohort would develop TB over their lifetime (2.7 per 1000, 2.4 to 3.1). For  
180 these individuals, the expected median time to TB was estimated to be 11.3 (IQR 3.1, 26.3)  
181 years, with 20.2% (18.6 to 21.7) of cases occurring within two years of U.S. arrival. The CDC  
182 Online Tuberculosis Information System Data reported 840 TB cases among non-US-born  
183 population within the first year they entered the U.S. in 2019, and our risk model estimated 770  
184 (95% CI 629 to 894) cases.<sup>18</sup>

185  
186 Figure 1 shows the projected number of TB cases by year under each strategy. In the no-  
187 screening and the IGRA-only strategies, the trend decreases monotonically. In contrast, the  
188 IGRA-HrTS and the HrTS-only strategies show a slight rebound after year one followed by a  
189 monotonic decrease thereafter, as HrTS identified most of the incipient TB at the time of  
190 screening. For the IGRA-HrTS and HrTS-only strategies, TB incidence reductions are  
191 concentrated in the years following screening, while the TB incidence reduction accumulates  
192 over a longer period, proportional to overall incidence trends, in the IGRA-only strategy.

193  
194 Compared to the no-screening strategy, the IGRA-only strategy was estimated to result in the  
195 greatest reduction (33.7%, 25.7 to 42.8) in TB cases over the lifetime of the entire study cohort,  
196 followed by the HrTS-only strategy (13.2%, 11.3 to 16.0) and the IGRA-HrTS strategy (10.4%,  
197 9.0 to 12.2) (Table 3). This pattern was consistent across risk categories.

198  
199 **Utilization of screening and treatment resources.** In the IGRA-only strategy, 11.1% (95% CI  
200 9.2 to 13.4) of the study cohort tested positive with IGRA, 1.1% (95% CI 0.9 to 1.4) tested  
201 positive with both IGRA and HrTS in the IGRA-HrTS strategy, and 10.0% (95% CI 9.99 to  
202 10.02) tested positive with HrTS in the HrTS-only strategy (Online Supplement Table E4). The  
203 proportions of the cohort receiving an intervention to prevent disease progression were more

204 than eight times higher in the IGRA-only strategy (8.5%, 7.1 to 10.3) and the HrTS-only strategy  
205 (8.8%, 7.8 to 9.6), compared to the IGRA-HrTS strategy (1.0 %, 0.8 to 1.2) (Table 3).

206  
207 The expected proportions treated for TB disease, identified through active or passive screening,  
208 were highest in the no-screening strategy, followed by the IGRA-HrTS strategy, and the IGRA-  
209 only strategy (Table 3).

210  
211 **PPV and NPV of screening algorithms.** Overall, the PPV for TB disease within two years  
212 (3.6%, 3.0 to 4.2) and over the lifetime (5.4%, 4.5 to 6.1) were highest in the IGRA-HrTS  
213 strategy. The PPV for TB disease within two years was the lowest in the IGRA-only strategy  
214 (0.4%, 0.3 to 0.5) and the PPV for TB disease over lifetime was the lowest in the HrTS-only  
215 strategy (0.8%, 0.7 to 0.8). Comparing across risk groups, PPV values were higher among  
216 migrant populations from countries with higher TB risks (Table 3). The NPV for future TB  
217 disease within two years and over lifetime were greater in lower risk categories, but were high  
218 overall for all strategies (Table 3).

219  
220 **Health benefits, costs, and cost-effectiveness.** Relative to the no-screening strategy, the  
221 IGRA-only strategy produced the greatest per-person gain in QALYs whereas the IGRA-HrTS  
222 strategy offered the least. From the healthcare sector perspective, the HrTS-only strategy  
223 incurred the greatest additional costs while the IGRA-only strategy incurred the least. From the  
224 societal perspective, the HrTS-only strategy was the costliest, while the IGRA-HrTS strategy  
225 was the least costly. Compared to the no-screening strategy, the IGRA-only strategy resulted in  
226 an ICER of US\$78,943 per QALY gained in the healthcare sector perspective and an ICER of  
227 \$89,431 in the societal perspective, dominating the IGRA-HrTS and HrTS-only strategies (Table  
228 4). The subgroup cost-effectiveness results are in Appendix 8 in the online supplement.

229

230 **Sensitivity analysis.** Two-way sensitivity analyses show that our cost-effectiveness analysis  
231 conclusion is robust to the cost of HrTS as well as the willingness to pay threshold (Online  
232 Supplement Figures E2-1, E2-2), even when the cost of HrTS is as low as \$15. Our four-way  
233 sensitivity analyses show that for the highest risk group, when the cost of HrTS is \$15, the  
234 HrTS-only strategy may be cost-effective from the societal perspective when HrTS has a >75%  
235 sensitivity for TB cases occurring seven years after testing, or nine years when analyzed from  
236 the healthcare sector perspective (Online Supplement Figures E3-1-1, E3-1-2).

237  
238 In an alternative scenario that assumed a more rapid decline in the rate of progression to TB  
239 disease following U.S. entry, the IGRA-only strategy remained the cost-effective strategy from  
240 both healthcare sector and societal perspectives, at a \$150,000 willingness-to-pay threshold  
241 and a \$30 HrTS. However, at a willingness-to-pay threshold to \$100,000 the IGRA-HrTS  
242 strategy would be cost-effective from the healthcare sector perspective (Online Supplement  
243 Table E11).

244

## 245 **Discussion**

246 To our knowledge, this is the first analysis to formally evaluate the cost-effectiveness of  
247 incorporating host transcriptomic signatures in post-arrival screening algorithms among  
248 migrants in a low-incidence country. In our main analysis, we found that, compared to the  
249 current recommendation of using IGRA to screen for and treat *Mtb* infection, it would not be  
250 cost-effective to use HrTS either as a rule-out test among IGRA positives or as a stand-alone  
251 rule-in test for incipient TB among newly arrived migrants in the United States, even if these  
252 tests meet the WHO TPP optimal criteria. In our study, HrTS was assumed to have a 90%  
253 sensitivity of TB cases occurring in the first two years after U.S. arrival, which represented 20%  
254 of TB cases occurring over the lifetime of our study cohort. HrTS only had a 10% sensitivity for  
255 the remaining cases. In contrast, while IGRA had a lower sensitivity for incipient cases, these

256 tests retained a 78% sensitivity for cases occurring after this initial two-year period, a key  
257 reason why the IGRA-only strategy dominated the other screening strategies.

258  
259 If HrTS could predict more cases with delayed onset, these new screening tools may be cost-  
260 effective. As we report in sensitivity analyses, the HrTS-only strategy would be preferred if HrTS  
261 retains at least a 75% sensitivity for TB cases occurring over at least the subsequent seven  
262 years. However, it is unlikely that HrTS signatures with high sensitivity over an interval longer  
263 than two years are imminent.<sup>17</sup> In addition, in an alternative scenario that assumed more rapid  
264 declines in the rate of progression to TB disease following U.S. entry, the health benefits  
265 estimated for the IGRA-only strategy were proportionally lower, and HrTS was found to be  
266 potentially cost-effective. In this analysis, the IGRA-HrTS strategy became the preferred  
267 strategy from the healthcare sector perspective for a willingness-to-pay threshold for \$100,000  
268 per QALY, indicating that the cost-effectiveness of HrTS depends on the long-term health  
269 benefits achieved with the current IGRA-only strategy. Additional studies estimating the  
270 dynamics of TB progression risk many years after migration would be valuable.

271  
272 We have evaluated only one specific use case of HrTS among recent migrants to low incidence  
273 settings, and HrTS may have greater value in settings with higher TB incidence. A modelling  
274 study by Sumner *et al.* showed that targeted TB preventive therapy guided by a blood  
275 transcriptomic biomarker (RISK11) may be more effective in averting TB cases than a one-off  
276 universal treatment amongst people living with HIV but would require repeat testing.<sup>26</sup> The  
277 modelled cohort they evaluated had a TB incidence rate much higher than in our study. They  
278 also reported that for the signature to be cost-effective, the cost of the test would need to be  
279 one-tenth of the preventive therapy regimen, assuming annual screening. HrTS could also be  
280 used to screen for active TB disease in migrant populations. However, a cost-effectiveness

281 analysis of HrTS for TB screening in adults with suspected TB disease in the United Kingdom  
282 showed that it would not be cost-effective compared to the status quo.<sup>27</sup>

283

284 We found that the IGRA-only strategy had the lowest PPV for incipient TB disease while the  
285 HrTS-only strategy had the lowest PPV for TB disease over the remaining lifetime. This reflects  
286 the assumption that after the initial two-year window, the HrTS has a 10% false positive rate,  
287 substantially higher than the 1.5% with IGRA. This result highlights that both the PPV and NPV  
288 are important metrics for quantifying the overall value provided by these predictive tests.

289 Compared to the PPV of IGRA reported in the UK PREDICT TB study (3.0%), our study found a  
290 lower PPV of IGRA (0.4% for TB within two years). However, in our study population, the TB  
291 incidence rate was 38 per 100,000 person-years in year 1 and 18 per 100,000 in year 2; in the  
292 PREDICT study, incidence was 932 per 100,000 in year 1 and 115 per 100,000 in year 2. Given  
293 that the PPV will be sensitive to the incidence rate in the population of interest, this difference in  
294 TB risk could explain the difference in PPV.

295

296 Our study has several strengths. First, we used an individual based model with granular, time-  
297 dependent TB risk estimates that are a function of each migrant's age, entry-year, country-of-  
298 origin, and years since U.S. arrival. This allowed us to estimate lifetime outcomes of the study  
299 cohort under different scenarios and evaluate the impact of HrTS in a real-world setting that has  
300 direct clinical and policy implications. The fact that the analysis captured lifetime outcomes is  
301 particularly important because HrTS is a predictive test for future TB disease; restricting the  
302 analytic timeframe could over-estimate the comparative effect of it relative to other screening  
303 tools.

304

305 Second, our analytic framework can be used to evaluate the performance of other predictive  
306 tests with sensitivity dependent on individual patient's time to disease in a setting where the

307 prevalence of a disease is also time-varying. Our approach showed that an individual-based  
308 discrete event simulation model has the flexibility to incorporate these two time-dependent  
309 elements. Third, our functional definitions of a 'positive test', a 'negative test', and a 'TB case' in  
310 PPV and NPV calculations provided a clear performance measure for a predictive test for future  
311 TB disease. This can be useful in evaluation of novel screening and diagnostic tools as the field  
312 has an increasing interest in tools that can identify individuals who are progressing from *Mtb*  
313 infection to TB disease.

314  
315 One limitation in our study is that we assumed conditional independence of IGRA and HrTS test  
316 results. If this assumption does not hold, we may over-estimate the sensitivity of the IGRA-HrTS  
317 strategy. We estimated country-specific LTBI prevalence among migrants based on a previously  
318 published study that focused on high-risk populations, which might not be representative of the  
319 general migrant population. To address this limitation, we calibrated the estimates so that the  
320 LTBI prevalence of the entire migrant population in our study matched the national non-US born  
321 LTBI prevalence estimate reported in NHANES. Other key assumptions we made in our study  
322 included the treatment uptake and completion rates and regimen efficacy for incipient TB.  
323 Screening and treatment of incipient TB is not routine clinical practice, and there is little  
324 empirical evidence to inform these estimates.

325  
326 Many signature tests have been proposed in recent years, with the goal of identifying individuals  
327 with a high proximal risk of developing TB disease.<sup>3,17</sup> Currently, none has met the WHO TPP  
328 optimal criteria. Our study suggests that even if the WHO TPP criteria were met, HrTS is  
329 unlikely to be cost-effective compared to the conventional IGRA test as a post-arrival screening  
330 tool among high-risk migrants in our setting.

## 331 **Acknowledgements**

332 We thank Dr. Andrew Hill for sharing the detailed results of the TB risk model reported in the  
333 study “Hill AN, *et al.* High-resolution estimates of tuberculosis incidence among non-U.S.-born  
334 persons residing in the United States, 2000–2016. *Epidemics* 2020; **33**: 100419”, which was  
335 funded by the U.S. Centers for Disease Control and Prevention, National Center for HIV/AIDS,  
336 Viral Hepatitis, STD, and TB Prevention Epidemiologic and Economic Modeling Agreement  
337 (#5NU38PS004644). We also thank Carla Winston, Michelle Van Handel, Julie Self, Suzanne  
338 Marks, and Garrett Asay from the U.S. CDC for their valuable input to our manuscript. The  
339 findings and conclusions in this paper are those of the authors and do not represent the view of  
340 the funding sources or the authors’ affiliated institutions.

341

## 342 **Data Sharing**

343 Analytic code and model inputs are available through the following link: << Link to GitHub  
344 repository removed for peer review. It will be made public when the manuscript is accepted and  
345 finalized >>. The detailed results of the TB risk model are available at << Dataverse link will be  
346 added when the manuscript is accepted and finalized >>.

347

## 348 **Declaration of interests**

349 We declare no competing interests.

## Reference

- 1 Houben RMGJ, Dodd PJ. The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling. *PLOS Med* 2016; **13**: e1002152.
- 2 Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. *Eur Respir J* 2019; **54**. DOI:10.1183/13993003.00655-2019.
- 3 Abubakar I, Drobniowski F, Southern J, *et al*. Prognostic value of interferon- $\gamma$  release assays and tuberculin skin test in predicting the development of active tuberculosis (UK PREDICT TB): a prospective cohort study. *Lancet Infect Dis* 2018; **18**: 1077–87.
- 4 Mahomed H, Ehrlich R, Hawkridge T, *et al*. TB Incidence in an Adolescent Cohort in South Africa. *PLoS ONE* 2013; **8**: e59652.
- 5 Zellweger J-P, Sotgiu G, Block M, *et al*. Risk Assessment of Tuberculosis in Contacts by IFN- $\gamma$  Release Assays. A Tuberculosis Network European Trials Group Study. *Am J Respir Crit Care Med* 2015; **191**: 1176–84.
- 6 Sharma SK, Vashishtha R, Chauhan LS, Sreenivas V, Seth D. Comparison of TST and IGRA in Diagnosis of Latent Tuberculosis Infection in a High TB-Burden Setting. *PLoS ONE* 2017; **12**: e0169539.
- 7 World Health Organization. Development of a Target Product Profile (TPP) and a framework for evaluation for a test for predicting progression from tuberculosis infection to active disease. 2017.
- 8 Scriba TJ, Fiore-Gartland A, Penn-Nicholson A, *et al*. Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial. *Lancet Infect Dis* 2021; **21**: 354–65.
- 9 Drain PK, Bajema KL, Dowdy D, *et al*. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection. *Clin Microbiol Rev* 2018; **31**: e00021-18.
- 10 White Z, Painter J, Douglas P, *et al*. Immigrant Arrival and Tuberculosis among Large Immigrant- and Refugee-Receiving Countries, 2005–2009. *Tuberc Res Treat* 2017; **2017**: e8567893.
- 11 Schwartz NG. Tuberculosis — United States, 2019. *MMWR Morb Mortal Wkly Rep* 2020; **69**. DOI:10.15585/mmwr.mm6911a3.
- 12 Yuen CM, Kammerer JS, Marks K, Navin TR, France AM. Recent Transmission of Tuberculosis - United States, 2011-2014. *PloS One* 2016; **11**: e0153728.
- 13 Zenner D, Hafezi H, Potter J, Capone S, Matteelli A. Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection. *Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis* 2017; **21**: 965–76.
- 14 Hill AN, Cohen T, Salomon JA, Menzies NA. High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000–2016. *Epidemics* 2020; **33**: 100419.



- 15 Hamada Y, Paulos L, Baruch NG, Cronin W. Proposed Approach for 4-Month Treatment of Culture-Negative Pulmonary Tuberculosis in Adults. *Ann Am Thorac Soc* 2016; **13**: 1657–8.
- 16 Stout JE, Wu Y, Ho CS, *et al.* Evaluating latent tuberculosis infection diagnostics using latent class analysis. *Thorax* 2018; **73**: 1062–70.
- 17 Gupta RK, Turner CT, Venturini C, *et al.* Concise whole blood transcriptional signatures for incipient tuberculosis: a systematic review and patient-level pooled meta-analysis. *Lancet Respir Med* 2020; **8**: 395–406.
- 18 Collins JM, Stout JE, Ayers T, *et al.* Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth—United States, 2012–2017. *Clin Infect Dis Off Publ Infect Dis Soc Am* 2020; **73**: e3468–75.
- 19 Mirzazadeh A, Kahn JG, Haddad MB, *et al.* State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. *PLOS ONE* 2021; **16**: e0249012.
- 20 Living Longer: Historical and Projected Life Expectancy in the United States, 1960 to 2060. .
- 21 Gillespie DT. A general method for numerically simulating the stochastic time evolution of coupled chemical reactions. *J Comput Phys* 1976; **22**: 403–34.
- 22 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. <https://www.R-project.org/>.
- 23 Neumann PJ, Ganiats TG, Russell LB, Sanders GD, Siegel JE, editors. Cost-Effectiveness in Health and Medicine. Oxford University Press, 2016  
DOI:10.1093/acprof:oso/9780190492939.001.0001.
- 24 Neumann PJ, Cohen JT, Weinstein MC. Updating Cost-Effectiveness — The Curious Resilience of the \$50,000-per-QALY Threshold. *N Engl J Med* 2014; **371**: 796–7.
- 25 Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. *Value Health* 2012; **15**: 835–42.
- 26 Sumner T, Mendelsohn SC, Scriba TJ, Hatherill M, White RG. The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study. *BMC Med* 2021; **19**: 252.
- 27 Halliday A, Jain P, Hoang L, *et al.* Health economic analysis. NIHR Journals Library, 2021 <https://www.ncbi.nlm.nih.gov/books/NBK569475/> (accessed Feb 15, 2023).

**Table 1. Characteristics of study cohort upon entry to the US in 2019**

Risk category <sup>1</sup>	Number of countries/regions	Countries/ regions <sup>2</sup>	Modelled population size, n (% of total population)	Mean entry age
Whole cohort	97		2,042,225 (100 %)	29.0
I	5	IDN, LBR, MMR, <b>PHL</b> , ZAF	100,778 (4.9 %)	34.0
II	19	AFG, BGD, BOL, CMR, ETH, GHA, HTI, <b>IND</b> , KEN, KHM, LAO, NGA, NPL, PAK, PER, SLE, SOM, THA, <b>VNM</b>	340,454 (16.7 %)	28.9
III	50	ALB, ARG, ARM, BGR, BIH, BLR, BLZ, BRA, CHL, <b>CHN</b> , COL, CPV, CRI, DOM, ECU, EGY, ESP, FJI, GTM, GUY, HKG, HND, IRN, IRQ, JPN, KOR, LBN, LKA, LTU, MAR, MDA, <b>MEX</b> , MYS, NIC, PAN, POL, PRT, ROU, RUS, SDN, SLV, SYR, TTO, TUR, TWN, UKR, URY, UZB, VEN, YEM	1,409,531 (69.0 %)	27.9
IV	23	AUS, AUT, BEL, BRB, CAN, CHE, CUB, CZE, DEU, FRA, GBR, GRC, GRD, HRV, HUN, IRL, ISR, ITA, JAM, JOR, NLD, SAU, SWE	191,462 (9.4 %)	34.7

<sup>1</sup> Epidemiological categorization of migrant populations based on TB incidence per 100k in 2019 for their country-of-origin: risk category I ( $\geq 300$ ); risk category II (100-300), risk category III (10-100), risk category IV (0-10).


<sup>2</sup> Countries highlighted in red are the top five country-of-origins that contribute to the total number of TB cases among migrants.

**Table 2. Testing and treatment decision rules**

Tests performed	Test results <sup>1</sup>			Diagnosis, conditional on test results	Treatment prescribed, conditional on diagnosis <sup>2</sup>
	IGRA	HrTS	TB diagnosis		
Strategy II (IGRA → TB diagnosis)	pos	--	pos	TB disease	Treatment for TB disease
	pos	--	neg	<i>Mtb</i> infection	Treatment for <i>Mtb</i> infection
	neg	--	--	No <i>Mtb</i> infection	No treatment
Strategy III (IGRA → HrTS → TB diagnosis)	pos	pos	pos	TB disease	Treatment for TB disease
	pos	pos	neg	Incipient TB	Treatment for incipient TB
	pos	neg	--	Non-progression <i>Mtb</i> infection	No treatment
	neg	--	--	No <i>Mtb</i> infection	No treatment
Strategy IV (HrTS → TB diagnosis)	--	pos	pos	TB disease	Treatment for TB disease
	--	pos	neg	Incipient TB	Treatment for incipient TB
	--	neg	--	No incipient TB	No treatment
In all strategies, in the case of TB diagnosis that occurred outside of the post-arrival screening	--	--	pos	TB disease	Treatment for TB disease

<sup>1</sup> pos, positive; neg, negative; TB diagnosis is assumed to be perfect.

<sup>2</sup> In this study, we assumed individuals were given 3HP for treatment for *Mtb* infection and one month of HR daily followed by three months of HR three times a week for treatment for incipient TB, a regimen that has been used for sputum negative TB cases.<sup>1</sup>



**Figure 1. Number of TB cases, by years since entry.** The circles represent the expected number of TB cases in each year, and the lines are fitted smooth lines to show the trend.

**Table 3. Testing and treatment outcomes**

	PPV for future TB disease (%, 95% CI)		NPV for future TB disease (%, 95% CI)		Percentage of population treated, by regimen type (%, 95% CI)			Reduction in TB cases (%, 95% CI)
	Within 2 years	Over lifetime	Within 2 years	Over lifetime	<i>Mtb</i> infection	Incipient TB	TB disease	
<b>Whole cohort</b>								
<i>No screening</i>	NA	NA	NA	NA	NA	NA	0.3 (0.2, 0.3)	<i>ref</i>
<i>IGRA only</i>	0.4 (0.3, 0.5)	2.0 (1.6, 2.3)	100 (100, 100)	99.9 (99.9, 100)	8.5 (7.1, 10.3)	NA	0.3 (0.1, 0.2)	33.7 (25.7, 42.8)
<i>IGRA-HrTS</i>	3.6 (3.0, 4.2)	5.4 (4.5, 6.1)	100 (100, 100)	99.8 (99.8, 99.8)	NA	1.0 (0.8, 1.2)	0.2 (0.2, 0.3)	10.4 (9.0, 12.2)
<i>HrTS only</i>	0.5 (0.5, 0.6)	0.8 (0.7, 0.8)	100 (100, 100)	99.8 (99.8, 99.8)	NA	8.8 (7.8, 9.6)	0.2 (0.2, 0.3)	13.2 (11.3, 16.0)
<b>Risk category I</b>								
<i>No screening</i>	NA	NA	NA	NA	NA	NA	0.9 (0.8, 1.0)	<i>ref</i>
<i>IGRA only</i>	1.0 (0.8, 1.2)	4.9 (4.1, 5.5)	99.9 (99.9, 100)	99.8 (99.6, 99.9)	11.3 (9.6, 13.1)	NA	0.6 (0.5, 0.8)	33.0 (25.0, 42.1)
<i>IGRA-HrTS</i>	8.5 (7.3, 9.9)	12.9 (11.1, 14.6)	99.9 (99.9, 100)	99.3 (99.2, 99.3)	NA	1.4 (1.1, 1.6)	0.8 (0.7, 0.9)	10.8 (9.4, 12.7)
<i>HrTS only</i>	1.7 (1.5, 1.9)	2.6 (2.3, 2.9)	100 (100, 100)	99.3 (99.2, 99.3)	NA	9.0 (8.0, 9.8)	0.8 (0.7, 0.9)	14.2 (12.0, 16.1)
<b>Risk category II</b>								
<i>No screening</i>	NA	NA	NA	NA	NA	NA	0.5 (0.4, 0.6)	<i>ref</i>
<i>IGRA only</i>	0.7 (0.6, 0.8)	3.1 (2.7, 3.6)	100 (100, 100)	99.9 (99.8, 99.9)	10.3 (8.7, 12.1)	NA	0.3 (0.2, 0.4)	36.6 (27.3, 47.1)
<i>IGRA-HrTS</i>	5.9 (4.8, 6.8)	8.8 (7.4, 10.1)	100 (100, 100)	99.6 (99.6, 99.6)	NA	1.3 (1.0, 1.5)	0.5 (0.4, 0.5)	11.5 (10.0, 12.7)
<i>HrTS only</i>	1.0 (0.8, 1.1)	1.4 (1.3, 1.6)	100 (100, 100)	99.6 (99.5, 99.6)	NA	8.9 (7.9, 9.7)	0.5 (0.4, 0.5)	13.2 (11.2, 15.5)
<b>Risk category III</b>								
<i>No screening</i>	NA	NA	NA	NA	NA	NA	0.2 (0.2, 0.2)	<i>ref</i>
<i>IGRA only</i>	0.3 (0.3, 0.3)	1.5 (1.2, 1.7)	100 (100, 100)	100 (100, 100)	8.4 (6.9, 10.1)	NA	0.1 (0.1, 0.2)	32.1 (24.8, 40.4)
<i>IGRA-HrTS</i>	2.7 (2.2, 3.1)	3.9 (3.3, 4.4)	100 (100, 100)	99.8 (99.8, 99.9)	NA	1.0 (0.8, 1.2)	0.2 (0.2, 0.2)	9.6 (8.3, 11.6)
<i>HrTS only</i>	0.4 (0.3, 0.4)	0.6 (0.5, 0.6)	100 (100, 100)	99.8 (99.8, 99.9)	NA	8.8 (7.8, 9.5)	0.2 (0.2, 0.2)	12.9 (11.3, 16.2)
<b>Risk category IV</b>								
<i>No screening</i>	NA	NA	NA	NA	NA	NA	0.02 (0.01, 0.02)	<i>ref</i>
<i>IGRA only</i>	0.03 (0.02, 0.04)	0.2 (0.1, 0.2)	100 (100, 100)	100 (100, 100)	4.8 (3.7, 6.6)	NA	0.01 (0.01, 0.02)	32.0 (27.5, 38.1)
<i>IGRA-HrTS</i>	0.3 (0.2, 0.4)	0.3 (0.2, 0.4)	100 (100, 100)	100 (100, 100)	NA	0.6 (0.4, 0.8)	0.01 (0.01, 0.02)	6.1 (2.5, 14.3)
<i>HrTS only</i>	0.03 (0.03, 0.04)	0.03 (0.03, 0.04)	100 (100, 100)	100 (100, 100)	NA	8.6 (7.6, 9.4)	0.01 (0.01, 0.02)	7.7 (2.5, 14.3)

As defined in the main text, risk categories are the epidemiological categorization of migrant populations based on TB incidence per 100k in 2019 for their country-of-origin: risk category I ( $\geq 300$ ); risk category II (100-300), risk category III (10-100), risk category IV (0-10).

**Table 4. Reference case cost-effectiveness results (time horizon: lifetime; costs and health effects incremental to the ‘no screening’ strategy, discounted at 3% annually)**

Strategy	TB related HC costs	Other HC expenditures	TB related non-HC costs	Other non-HC expenditures	Productivity gain <sup>1</sup>	Total Costs <sup>2</sup> \$	Total QALY gain	Inc. Cost <sup>2</sup>	Inc. Effectiveness <sup>3</sup> (QALYs)	ICER	Inc. NMB <sup>4</sup>
<b>Healthcare Sector Perspective</b>											
<b>IGRA only</b>	92.4 (67.4, 121.7)	4.6 (2.4, 6.7)	--	--	--	97.1 (72.4, 126.4)	0.00123 (0.00083, 0.00168)	97.1	0.00123	78,943	87.4
<b>IGRA-HrTS</b>	71.1 (55.4, 89.0)	1.1 (0.6, 1.7)	--	--	--	72.2 (56.4, 90.2)	0.00082 (0.00048, 0.00120)	NA	NA	Extended dominated	50.8
<b>HrTS only</b>	75.4 (55.5, 101.7)	1.3 (0.7, 2.0)	--	--	--	76.7 (56.8, 103.0)	0.00077 (0.00038, 0.00118)	NA	NA	Dominated	38.8
<b>Societal Perspective</b>											
<b>IGRA only</b>	92.4 (67.4, 121.7)	4.6 (2.4, 6.7)	6.8 (4.4, 9.6)	16.2 (8.1, 23.6)	10.1 (4.5, 14.8)	110.0 (85.3, 140.1)	0.00123 (0.00083, 0.00168)	110.0	0.00123	89,431	74.5
<b>IGRA-HrTS</b>	71.1 (55.4, 89.0)	1.1 (0.6, 1.7)	1.1 (0.4, 1.7)	4.9 (2.6, 7.2)	4.7 (1.4, 8.3)	73.4 (57.6, 91.8)	0.00082 (0.00048, 0.00120)	NA	NA	Extended Dominated	49.6
<b>HrTS only</b>	75.4 (55.5, 101.7)	1.3 (0.7, 2.0)	12.5 (9.9, 15.3)	5.6 (2.8, 8.4)	5.2 (1.7, 9.0)	89.6 (69.2, 115.9)	0.00077 (0.00038, 0.00118)	NA	NA	Dominated	25.9

Notes: HC, healthcare; QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio; NMB, net monetary benefit

- 1 All costs, expenditures, productivity gain, and QALY gain were estimated relative to the “No Screening” strategy.
- 2 Productivity gain was attributable to mortality aversion.
- 3 For analysis in the healthcare sector perspective, Total Costs = (TB related healthcare costs + Other healthcare expenditures); for analysis in the societal perspective, Total Costs = (TB related healthcare costs + Other healthcare expenditures + TB related non-healthcare costs + Other non-healthcare expenditures – Productivity gain)
- 4 The Inc. cost and Inc. effectiveness in columns 9-10 were estimated relative to the next best strategy.
- 5 The NMB were based on \$150,000/QALY; Inc. NMB = (Inc. effectiveness\* \$150,000/QALY) – Inc. costs